Summary
Celcuity: REVTORPYK Is Now A Commercial Story
Celcuity Inc. remains a Buy as the REVTORPYK/gedatolisib FDA approval and rapid NCCN Category 1 inclusion de-risk clinical and commercial adoption. CELC's financials reflect a front-loaded commercial investment, with SG&A surging for launch, but a strengthened $754M cash position provides funding visibility into 2029. VIKTORIA-1 data show REVTORPYK delivers a step-change in efficacy and tolerability, supporting rapid physician adoption and a potential blockbuster franchise.
Celcuity Inc. (CELC) Q2 2026 Earnings Call Transcript
Celcuity Inc. (CELC) Q2 2026 Earnings Call Transcript
Celcuity Q2 Earnings Call Highlights
Celcuity NASDAQ: CELC said it remains on track to begin commercial shipments of REVTORPYK, its gedatolisib therapy for certain patients with advanced breast cancer, late in the third quarter of 2026 following its recent FDA approval.
Celcuity Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Madelyn D. Purcell Pfizer Inc | 295,652 | $3.87M | $27.22M | $23.35M | 603.44% |
 Curtis Ellergodt Rothschild Investment LLC | 98 | $3,599.7 | $9,104.2 | $5,504.5 | 152.92% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 1,000 | $114,140 | $88,110 | -$26,030 | -22.81% |
| NA Nizar Araji National Bank Of Canada /FI/ | 5 | $512.6 | $453.95 | -$58.65 | -11.44% |
| SN Stephanie Nee HARBOR CAPITAL ADVISORS Inc. | 19,933 | $1.72M | $1.85M | $134,164.06 | 7.82% |
Celcuity Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| EFV Eva Fortea Verdejo Wells Fargo | 307.74 | $31,803.01 | $28,588.61 | -$3,214.4 | -10.11% |
| AN Alexander Nowak Craig-Hallum | 1,090.29 | $96,763.09 | $89,905.16 | -$6,857.93 | -7.09% |
Celcuity Inc. (CELC) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Celcuity Inc. ever had a stock split?
Celcuity Inc. Profile
| Biotechnology Industry | Healthcare Sector | Brian F. Sullivan CEO | NASDAQ (CM) Exchange | 15102K100 CUSIP |
| US Country | 155 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Celcuity Inc. is a clinical-stage biotechnology company based in Minneapolis, Minnesota, established in 2011. It is primarily engaged in the development of targeted therapies for the treatment of various solid tumors. By focusing on personalized medicine, Celcuity aims to advance the treatment of cancer through its innovative CELsignia diagnostic platform. This platform utilizes living tumor cells from patients to pinpoint the specific abnormal cellular processes driving their cancer. An essential aspect of their operation includes a strategic license agreement with Pfizer, Inc., granting them the development and commercialization rights to Gedatolisib, one of their leading drug candidates.
Products and Services
- CELsignia Diagnostic Platform:
This groundbreaking platform represents the core of Celcuity's technological advancement. It is designed to analyze living tumor cells to determine the specific abnormal cellular activity causing a patient's cancer. The analysis enables the identification of targeted therapies that are most likely to be effective for each patient, personalizing the treatment approach to cancer care.
- Gedatolisib:
As a leading drug candidate in Celcuity's portfolio, Gedatolisib is being developed to selectively target and inhibit the activity of class I isoforms of phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR). These enzymes are often involved in the growth and spread of cancer cells. Gedatolisib is currently focused on the treatment of patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer, and metastatic castration-resistant prostate cancer. The development and potential commercialization of Gedatolisib are underpinned by a license agreement with Pfizer, Inc., illustrating Celcuity's collaborative efforts with industry leaders to bring new cancer therapies to market.
